ATE350375T1 - 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen - Google Patents

17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen

Info

Publication number
ATE350375T1
ATE350375T1 AT02761567T AT02761567T ATE350375T1 AT E350375 T1 ATE350375 T1 AT E350375T1 AT 02761567 T AT02761567 T AT 02761567T AT 02761567 T AT02761567 T AT 02761567T AT E350375 T1 ATE350375 T1 AT E350375T1
Authority
AT
Austria
Prior art keywords
17beta
androgen
inhibitors
treatment
hydroxysteroid dehydrogenase
Prior art date
Application number
AT02761567T
Other languages
English (en)
Inventor
Timothy J Guzi
Kamil Paruch
Alan K Mallams
Jocelyn D Rivera
Ronald J Doll
Viyyoor M Girijavallabhan
Jonathan Pachter
Yi-Tsung Liu
Anil K Saksena
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE350375T1 publication Critical patent/ATE350375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02761567T 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen ATE350375T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31771501P 2001-09-06 2001-09-06

Publications (1)

Publication Number Publication Date
ATE350375T1 true ATE350375T1 (de) 2007-01-15

Family

ID=23234950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761567T ATE350375T1 (de) 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen

Country Status (29)

Country Link
US (3) US6903102B2 (de)
EP (1) EP1423381B1 (de)
JP (1) JP4320252B2 (de)
KR (1) KR100991616B1 (de)
CN (1) CN1551878B (de)
AR (1) AR036492A1 (de)
AT (1) ATE350375T1 (de)
AU (1) AU2002326823B2 (de)
BR (1) BR0212378A (de)
CA (1) CA2459311C (de)
CY (1) CY1106521T1 (de)
DE (1) DE60217363T2 (de)
DK (1) DK1423381T3 (de)
EC (1) ECSP045004A (de)
ES (1) ES2276950T3 (de)
HU (1) HUP0402629A3 (de)
IL (2) IL160065A0 (de)
MX (1) MXPA04002167A (de)
MY (1) MY141661A (de)
NO (1) NO327254B1 (de)
NZ (1) NZ530810A (de)
PE (1) PE20030703A1 (de)
PL (1) PL369108A1 (de)
PT (1) PT1423381E (de)
RU (1) RU2315763C2 (de)
SI (1) SI1423381T1 (de)
TW (1) TWI329108B (de)
WO (1) WO2003022835A1 (de)
ZA (1) ZA200401456B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (de) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
JP4614770B2 (ja) 2002-11-18 2011-01-19 シェーリング コーポレイション アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター
ATE409065T1 (de) * 2002-12-17 2008-10-15 Schering Corp Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
WO2005058281A1 (en) * 2003-12-17 2005-06-30 Schering Corporation Hydroxysteroid dehydrogenase inhibitors adsorbed on hydrophilic carriers
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US7138246B2 (en) 2004-03-01 2006-11-21 Bristol-Myers Squibb Company Methods for identifying or screening for agents that modulate 17β-HSD3
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8884061B2 (en) * 2006-03-03 2014-11-11 Colorado State University Research Foundation Compositions and methods of use of electron transport system inhibitors
BRPI0710468A2 (pt) * 2006-04-24 2011-08-16 Lilly Co Eli composto, e, composição farmacêutica
PT2029529E (pt) * 2006-04-24 2010-09-02 Lilly Co Eli Pirrolidinonas substituídas como inibidores de 11 betahidroxiesteróide desidrogenase
ES2452822T3 (es) 2006-06-28 2014-04-02 Amgen Inc. Inhibidores del transportador 1 de glicina
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
EP2119709A4 (de) 2007-02-09 2011-08-17 Kaneka Corp Verfahren zur herstellung eines optisch aktiven 2-arylpiperazinderivats
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
CA2844985A1 (en) 2011-08-16 2013-02-21 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
EP2961409A1 (de) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitoren von cdk8/19 zur verwendung bei der behandlung von östrogenrezeptorpositivem brustkrebs
AR096729A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados terapéuticamente activos de estratien-tiazol
WO2014207309A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
WO2014207311A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1
CN105530940A (zh) * 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
CN103755626A (zh) * 2014-01-23 2014-04-30 安徽安腾药业有限责任公司 一种贝托斯汀关键中间体的合成方法
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN107207561B (zh) 2014-12-23 2020-03-31 佛恩多制药有限公司 17β-HSD1–抑制剂的前药
EP3237430B1 (de) 2014-12-23 2019-03-20 Forendo Pharma Ltd PRODRUGS VON 17ß-HSD1-INHIBITOREN
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
US20210084900A1 (en) 2017-05-04 2021-03-25 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for Combating Phytopathogenic Fungi
UA126342C2 (uk) 2017-06-08 2022-09-21 Форендо Фарма Лтд 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ
MX2021006452A (es) 2018-12-05 2021-09-28 Forendo Pharma Ltd Compuestos estra-1,3,5(10)-trieno condensados en posición 16(17) con un anillo de pirazol como inhibidores de 17-hsd1.
MA56457A (fr) * 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation
US20220313581A1 (en) 2019-08-28 2022-10-06 Conopco, Inc. , d/b/a UNILEVER Novel compounds for skin lightening
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594309B2 (en) 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
DE69022722T2 (de) 1989-03-10 1996-05-02 Endorecherche Inc., Ste-Foy, Quebec Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
AU5851690A (en) 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
ES2222633T3 (es) 1989-07-07 2005-02-01 Endorecherche Inc. Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
SK31793A3 (en) 1990-10-10 1993-09-08 Schering Corp Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines and piperazines and compositions and methods of use thereof
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
EP0635012B1 (de) 1992-03-27 1996-07-10 Schering Corporation Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
US5620989A (en) 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
AU682838B2 (en) 1992-12-14 1997-10-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
DE69329649D1 (de) 1993-05-17 2000-12-14 Endorech Inc Verbesserte antiandrogene
WO1994029309A1 (en) 1993-06-07 1994-12-22 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
EP0739336B1 (de) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-bissubstituierte azazyclische tachykinin-antagonisten
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
PL346795A1 (en) * 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
US6063926A (en) 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
WO2000043008A1 (en) 1999-01-25 2000-07-27 Smithkline Beecham Corporation Anti-androgens and methods for treating disease
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
KR20020073586A (ko) * 2000-02-11 2002-09-27 버텍스 파마슈티칼스 인코포레이티드 피페라진 및 피페리딘 유도체

Also Published As

Publication number Publication date
DK1423381T3 (da) 2007-05-07
AR036492A1 (es) 2004-09-15
US20040132736A1 (en) 2004-07-08
TWI329108B (en) 2010-08-21
US6903102B2 (en) 2005-06-07
NZ530810A (en) 2006-05-26
CY1106521T1 (el) 2012-01-25
IL160065A0 (en) 2004-06-20
US20060014755A1 (en) 2006-01-19
AU2002326823B2 (en) 2005-12-15
PE20030703A1 (es) 2003-08-21
MXPA04002167A (es) 2004-06-29
RU2315763C2 (ru) 2008-01-27
HUP0402629A3 (en) 2009-09-28
WO2003022835A1 (en) 2003-03-20
KR20040031042A (ko) 2004-04-09
PL369108A1 (en) 2005-04-18
NO327254B1 (no) 2009-05-25
DE60217363T2 (de) 2007-10-11
US7432268B2 (en) 2008-10-07
JP4320252B2 (ja) 2009-08-26
SI1423381T1 (sl) 2007-04-30
KR100991616B1 (ko) 2010-11-04
DE60217363D1 (de) 2007-02-15
US20060069103A1 (en) 2006-03-30
CN1551878B (zh) 2011-08-10
BR0212378A (pt) 2004-10-19
JP2005502705A (ja) 2005-01-27
CA2459311C (en) 2010-08-03
ECSP045004A (es) 2004-04-28
HK1062677A1 (en) 2004-11-19
MY141661A (en) 2010-05-31
ZA200401456B (en) 2004-10-19
EP1423381B1 (de) 2007-01-03
CN1551878A (zh) 2004-12-01
ES2276950T3 (es) 2007-07-01
US7138396B2 (en) 2006-11-21
IL160065A (en) 2009-07-20
RU2004110410A (ru) 2005-10-20
PT1423381E (pt) 2007-04-30
CA2459311A1 (en) 2003-03-20
EP1423381A1 (de) 2004-06-02
NO20041452L (no) 2004-06-04
HUP0402629A2 (hu) 2005-05-30

Similar Documents

Publication Publication Date Title
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
ATE273304T1 (de) (s)-4-amino-5-chloro-2-methoxy-n-(1-(1-(2- tetrahydrofuryl-carbonyl)-4-piperidinylmethyl)- - piperidinyl)benzamid zur behandlung von magen- darmbewegungskrankheiten
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
EP1494696A4 (de) Behandlung von lungenerkrankungen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423381

Country of ref document: EP